ab80594 detects soluble P glycoprotein in the cultured media of viable adriamycin-resistant cells, whereas those of the drug-sensitive parent cells contain no detectable level of soluble P glycoprotein. We have data to indicate that this antibody may not cross react with Mouse. However, this has not been conclusively tested and expression levels may vary in certain cell lines/tissues.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Flow Cyt: Use at an assay dependent dilution.
ICC/IF: Use at an assay dependent dilution.
IHC-P: Use at an assay dependent dilution.
WB: Use at a concentration of 1 - 2 µg/ml. Predicted molecular weight: 141 kDa.
Not yet tested in other applications.
Optimal dilutions/concentrations should be determined by the end user.
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Expressed in liver, kidney, small intestine and brain.
Involvement in disease
Genetic variations in ABCB1 are associated with susceptibility to inflammatory bowel disease type 13 (IBD13) [MIM:612244]. Inflammatory bowel disease is characterized by a chronic relapsing intestinal inflammation. It is subdivided into Crohn disease and ulcerative colitis phenotypes. Crohn disease may involve any part of the gastrointestinal tract, but most frequently the terminal ileum and colon. Bowel inflammation is transmural and discontinuous; it may contain granulomas or be associated with intestinal or perianal fistulas. In contrast, in ulcerative colitis, the inflammation is continuous and limited to rectal and colonic mucosal layers; fistulas and granulomas are not observed. Both diseases include extraintestinal inflammation of the skin, eyes, or joints. Crohn disease and ulcerative colitis are commonly classified as autoimmune diseases.
References for Anti-P Glycoprotein antibody [F4] (ab80594)
This product has been referenced in:
Mesgari Abbasi M et al. The Effects of Cetirizine on P-glycoprotein Expression and Function In vitro and In situ. Adv Pharm Bull6:111-8 (2016).
Read more (PubMed: 27123426) »
Ganta S et al. Formulation development of a novel targeted theranostic nanoemulsion of docetaxel to overcome multidrug resistance in ovarian cancer. Drug Deliv23:968-80 (2016).
Read more (PubMed: 24901206) »